The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type

Beatriz G de la Torre; Fernando Albericio

doi:10.3390/molecules22030368

The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type

Molecules. 2017 Feb 27;22(3):368. doi: 10.3390/molecules22030368.

Authors

Beatriz G de la Torre¹, Fernando Albericio^{2

3

4}

Affiliations

¹ School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, 4001 Durban, South Africa. garciadelatorreb@ukzn.ac.za.
² School of Chemistry, University of KwaZulu-Natal, 4001 Durban, South Africa. albericio@ukzn.ac.za.
³ CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, University of Barcelona, 08028 Barcelona, Spain. albericio@ukzn.ac.za.
⁴ Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain. albericio@ukzn.ac.za.

Abstract

This is an analysis from a chemical point of view of the 22 drugs accepted by the FDA during 2016. The different drugs from the 2016 "harvest" have been classified according to their chemical structure: antibodies; TIDES (oligonucleotides and peptides); amino acids and natural products; drug combination; and small molecules.

Keywords: API; biologics; chemical entities; drug discovery; peptide; small molecules.

Publication types

Review

MeSH terms

Amino Acids / chemistry
Antibodies / chemistry
Biological Products / chemistry*
Databases, Pharmaceutical / statistics & numerical data
Drug Approval*
Drug Industry
Humans
Molecular Structure
Pharmaceutical Preparations / chemistry*
Small Molecule Libraries / chemistry
United States
United States Food and Drug Administration

Substances

Amino Acids
Antibodies
Biological Products
Pharmaceutical Preparations
Small Molecule Libraries